Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- IBTA -19.3%, HROW -18.9%, TSHA -14.5%, ZK -10.4%, AFYA -8.7%, NU -6.5%, AAP -6.2%, JJSF -6%, TTEK -5.5%, BILI -4.8%, BV -3.7%, NICE -3.7%, HP -3.3%, DADA -3.2%, CSCO -3%, DDD -1.7% (guides Q3 revs below consensus; also to delay 10-Q filing), JD -1%
Other news:
- JTAI -13.8% (stock offering by selling shareholder)
- NVCT -11.8% (Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer)
- ZLAB -6.3% (commences $200 mln ADS offering)
- CPRI -5.6% (Capri Holdings (CPRI) announces termination of merger with TPR)
- DMAC -4.2% (announces dosing of first patient in Phase 2 Trial of DM199)
- BFH -3.2% (provides performance update for October 2024: End-of-period credit card and other loans $17.9 bln vs. $18.4 bln last year)
- RYTM -2.6% (publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology)
- BABA -1.6% (Soros Capital new position)
- ENGN -1.5% (files $300 mln mixed shelf securities offering; also stock offering by selling shareholders)
- ODD -1.4% (fund to sell $100 mln of shares back to ODD)
- FLUT -1.1% (Soros Capital increases position)
- SLRN -1% (files $400 mln mixed shelf securities offering)
- VTR -1% (commences 10.6 mln share offering)